australasian society of clinical immunology and allergy

24 January 2024

Professor Andrew Wilson
Chair, Pharmaceutical Benefits Advisory Committee (PBAC)
MDP 952, GPO Box 9848
Canberra, ACT 2601
Email: pbac@health.gov.au

Dear Professor Wilson,

Re: Tavneos® (Avacopan) application for severe active granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA) in combination with rituximab or cyclophosphamide.

On behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA), we write in support of the resubmission of the application from Seqirus (Australia) Pty Ltd for General Schedule Authority Required (streamlined) Pharmaceutical Benefits Scheme (PBS) listing of Tavneos® (Avacopan) for treatment of severe active GPA and severe active MPA, in combination with rituximab or cyclophosphamide.

ASCIA supports the PBS listing of Tavneos® (Avacopan) for the following reasons:

- Clinical immunology/allergy specialists manage patients with vasculitis disorders including GPA and MPA, but current treatments have limitations, including effectiveness in controlling disease and side effects.
- There are considerable costs to patients and the healthcare system due to delayed or inadequate treatment of severe GPA and MPA, associated with medical consultations for poorly controlled disease.
- The new PBS listing of Tavneos® should improve access to effective therapeutic options for patients with severe GPA and MPA, which can be lifelong and impact quality of life.

We hope that the PBAC will take into account the reasons listed above, in support of the application for PBS listing of Tavneos®.

Yours sincerely,

A/Professor Theresa Cole
ASCIA President

Jill Smith
ASCIA CEO

Correspondence: Email jill@allergy.org.au